MYMD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 USD | +1.07% |
|
+13.60% | -63.41% |
| Apr. 18 | MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer | CI |
| Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 228.1 | 45.39 | 13.17 |
| Enterprise Value (EV) 1 | 216.7 | 40.7 | 8.294 |
| P/E ratio | -7.1 x | -2.94 x | -1.46 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -7.69 x | - | - |
| EV / FCF | -50,618,358 x | -6,166,655 x | -1,574,659 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 9.71 x | 3.12 x | 1.28 x |
| Nbr of stocks (in thousands) | 1,255 | 1,316 | 1,697 |
| Reference price 2 | 181.8 | 34.50 | 7.761 |
| Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -18.05 | -9.374 | -7.537 | -28.18 | - | - |
| EBIT 1 | -18.07 | -9.393 | -7.555 | -28.2 | -15.28 | -16.36 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.07 | -9.639 | -8.93 | -29.89 | -15.2 | -4 |
| Net income 1 | -18.07 | -9.639 | -8.93 | -29.89 | -15.2 | -4 |
| Net margin | - | - | - | - | - | - |
| EPS | - | -7.597 | -6.689 | -25.61 | -11.74 | -5.330 |
| Free Cash Flow | - | -1.705 | -1.179 | -4.282 | -6.599 | -5.267 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 1/15/21 | 1/15/21 | 3/19/21 | 3/31/22 | 3/31/23 | 4/1/24 |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.87 | 2.89 | - | - | - |
| Net Cash position 1 | 0.56 | - | - | 11.4 | 4.69 | 4.87 |
| Leverage (Debt/EBITDA) | - | -0.0931 x | -0.3839 x | - | - | - |
| Free Cash Flow | - | -1.71 | -1.18 | -4.28 | -6.6 | -5.27 |
| ROE (net income / shareholders' equity) | - | 1,271% | 307% | -325% | -79.3% | -29.1% |
| ROA (Net income/ Total Assets) | - | -1,525% | -3,119% | -138% | -45.1% | -57.8% |
| Assets 1 | - | 0.6322 | 0.2863 | 21.61 | 33.69 | 6.924 |
| Book Value Per Share | - | -1.360 | -3.070 | 18.70 | 11.10 | 6.060 |
| Cash Flow per Share | - | 0.1000 | 0.1000 | 0.4400 | 0.5700 | 1.330 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 1/15/21 | 1/15/21 | 3/19/21 | 3/31/22 | 3/31/23 | 4/1/24 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -63.41% | 6.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MYMD Stock
- Financials MyMD Pharmaceuticals, Inc.
